Rare and often misunderstood, neuroendocrine neoplasms (NENs) can be a challenge for providers, as well as patients. In this presentation, we will explore the complicated nomenclature used to describe and differentiate NENs and discuss best practices for patient communication and documentation. We will review hereditary tumor predisposition conditions associated with an increased risk for NENs with a focus on recent literature regarding the yield of germline genetic testing in NEN patient groups. We will also highlight germline genetic testing indications suggested by national guidelines. The presentation will demonstrate the progress that has been made in our understanding of germline risk for NENs while illustrating the critical need for future research in this area.
Level of Instruction: Intermediate
Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.
Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.
